Loading asset research
Immix Biopharma Inc. Common Stock
IMMXNasdaq · USD · StocksQuote as of · Exchange session not verified$12.13
-4.49%
Today
IMMX
Loading 1D prices…
Market cap
$868.5M
Volume
1.2M
52w high
$15.1052w low
$1.94Company profile
Immix Biopharma Inc. Common Stock
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Los Angeles, CA, United States
Employees
21
Fiscal year end
1231
CIK
1873835
Session & valuation
Open$12.86
Previous close$12.70
Day high$13.29
Day low$12.02
30-day avg. volume1.5M
Outstanding shares71.5M
Diluted EPS-$0.89
Latest annual period
P/E (trailing)-13.63
P/E (forward)-13.29
Price / book3.79
Beta0.20
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| GERNGeron Corporation Common Stock | $867.3M | $183.9M | -45.41% | -$0.13 | -1.82% | Hold |
| AVTXAvalo Therapeutics Inc. Common Stock | $864.5M | $59K | -132642.37% | -$5.84 | -6.17% | Buy |
| RIGLRigel Pharmaceuticals Inc. Common Stock | $882.4M | $294.3M | +124.72% | $19.48 | -0.08% | Buy |
| TBPHTheravance Biopharma Inc. Ordinary Shares | $883.1M | $107.5M | +98.54% | $2.06 | -0.00% | Hold |
| LXRXLexicon Pharmaceuticals Inc. Common Stock | $889.9M | $49.8M | -101.08% | -$0.14 | -1.24% | Buy |